Systemic Steroids Suppress Antimelanocyte Antibodies in Vitiligo

1997 ◽  
Vol 1 (4) ◽  
pp. 193-195 ◽  
Author(s):  
Seung-Kyung Hann ◽  
Dunlu Chen ◽  
Jean-Claude Bystryn
Keyword(s):  
Clinical Response ◽  
Steroid Treatment ◽  
Response To Therapy ◽  
Response To Treatment ◽  
Systemic Steroid ◽  
Good Clinical Response ◽  
Systemic Steroid Therapy ◽  
Initiation Of Therapy ◽  
Antibody Levels

Background: Vitiligo is associated with autoantibodies to melanocytes. The role of these antibodies in the pathogenesis of the disease is still unknown. Objective: The purpose of this study was to examine the role of vitiligo antibodies in the pathogenesis of the disease by studying whether or not there is a correlation between changes in their level and response to therapy with systemic steroid. Methods: Antibodies to the 40 to 45 kD, 75 kD, and 90 kD vitiligo antigens were measured prior to and following systemic steroid therapy in 10 patients with active vitiligo. Results: Four months following initiation of therapy, seven (78%) of nine patients with good clinical response to steroid treatment had a significant decrease in the level of vitiligo antibodies. By contrast, one patient who had no response to treatment had a slight increase in antibody levels. Conclusion: These findings suggest that one mechanism by which corticosteroids can cause repigmentation in vitiligo is by decreasing the level of vitiligo antibodies, and support the notion that vitiligo antibodies are involved in the pathogenesis of this disease.

Intratympanic Steroid Treatment for Sudden Hearing Loss after Failure of Systemic Steroid Therapy

2012 ◽  
Vol 105 (6) ◽  
pp. 513-520
Author(s):  
Toshiro Kawano ◽  
Junichi Ishitoya ◽  
Mariko Hirama ◽  
Yukiko Yamashita ◽  
Ryo Ikoma ◽  
...  
Keyword(s):  
Hearing Loss ◽  
Steroid Therapy ◽  
Sudden Hearing Loss ◽  
Steroid Treatment ◽  
Systemic Steroid ◽  
Systemic Steroid Therapy

scholarly journals Systemic steroid treatment of acute inflammation of ear and upper airways

2017 ◽  
Vol 95 (4) ◽  
pp. 369-374
Author(s):  
A. N. Slavsky ◽  
I. Yu. Meitel ◽  
L. A. Toporkova ◽  
V. I. Fatiyanova
Keyword(s):  
Otitis Media ◽  
Steroid Therapy ◽  
Acute Inflammation ◽  
Acute Otitis Media ◽  
Scientific Research ◽  
Steroid Treatment ◽  
Systemic Steroid ◽  
Upper Airways ◽  
Acute Rhinosinusitis ◽  
Systemic Steroid Therapy

This article was designed to review data on systemic steroid therapy of acute tonsillopharyngitis, acute rhinosinusitis, acute otitis media and mastoiditis borrowed from clinical recommendations, guidelines and scientific research.

scholarly journals Urinary tract infection by Acinetobacter dijkshoorniae and good clinical response to treatment

2020 ◽  
Vol 33 (4) ◽  
pp. 281-282
Author(s):  
María Isabel Casanovas Moreno-Torres ◽  
Fanny Rodríguez-Campos ◽  
Miguel Gutiérrez-Soto ◽  
José María Navarro-Marí ◽  
José Gutiérrez-Fernández
Keyword(s):  
Urinary Tract Infection ◽  
Urinary Tract ◽  
Tract Infection ◽  
Clinical Response ◽  
Response To Treatment ◽  
Good Clinical Response

scholarly journals The Subcutaneous Injection of Organophosphate: A Case Report

2021 ◽  
Vol 11 (4) ◽  
pp. 34343-34343
Author(s):  
Shafeajafar Zoofaghari ◽  
◽  
Afshar Fazeli Dehkordi ◽  
Kourosh Nemati ◽  
Mozhdeh Hashemzadeh ◽  
...  
Keyword(s):  
Developing Countries ◽  
Case Report ◽  
Clinical Response ◽  
Subcutaneous Injection ◽  
Nausea And Vomiting ◽  
Response To Treatment ◽  
Good Clinical Response ◽  
Current Case ◽  
Parenteral Route ◽  
Successful Recovery

Organophosphate (OP) poisoning is prevalent in developing countries. Toxicity occurs by voluntary injection, inhalation, and absorption. Self-injection is rare. The current case report describes a 61-y/o male with subcutaneous self-injected one cc OP poisoning presenting with delayed drowsiness, nausea, and vomiting. He was treated and presented a good clinical response to treatment with pralidoxime and had a successful recovery. Diagnosis of OP compound toxicity by the parenteral route is a challenge. By observing patients, the dose, and the time between poisoning until the time to start treatment, we can conclude different presentations and outcomes of OP poisoning.

scholarly journals MiR-4668 as a Novel Potential Biomarker for Eosinophilic Esophagitis

2020 ◽  
Vol 11 ◽  
pp. 215265672095337
Author(s):  
Neeti Bhardwaj ◽  
Maria Sena ◽  
Gisoo Ghaffari ◽  
Faoud Ishmael
Keyword(s):  
Eosinophilic Esophagitis ◽  
Mirna Expression ◽  
Saliva Sample ◽  
Allergic Diseases ◽  
Response To Therapy ◽  
Response To Treatment ◽  
Potential Biomarker ◽  
Before And After ◽  
Interesting Candidate

Introduction Eosinophilic esophagitis (EoE) is a clinico-pathological diagnosis characterized by esophageal dysfunction and eosinophilic infiltration of the esophagus. Demonstration of esophageal eosinophilia (more than 15 eosinophils/hpf) in biopsy specimen obtained by esophagogastroduodenoscopy (EGD) continues to be the gold standard for diagnosis and monitoring of response to therapy. There is a growing necessity for non-invasive biomarkers that can accurately diagnose this condition and assess response to therapy. While microRNAs (miRNA) are being investigated in allergic diseases, including EoE, not many studies have explored the role of salivary miRNAs in EoE. MiR-4668-5p is a particularly interesting candidate, as it is predicted to regulate TGF-beta signaling and has not previously been identified as a target in any allergy disease. We sought to further investigate the role of miR-4668 as a biomarker to characterize and monitor response to treatment with swallowed topical glucocorticoids. Methods After IRB approval, twenty-two adult patients with EoE were randomly enrolled to provide a saliva sample before and after 2 months of swallowed fluticasone therapy. Differences of miRNA expression before and after treatment were analyzed by paired T-test. A significance cutoff of <0.05 was used for all analyses. Results Expression of miR-4668 was higher in EoE vs. non-EoE subjects. The level of miR-4668 decreased in all subjects except one, with a mean fold change 0.49 ± 0.25. There was an association between miRNA expression and number of positive aeroallergens. The miR-4668 high group had a higher number of positive aeroallergen tests, while the miR-4668 low group had a greater number of subjects with drug allergies. Conclusions In this study, we identified that salivary miRNAs may serve as biomarkers to characterize EoE and response to topical corticosteroids. We specifically identified miR-4668 as a novel potential biomarker, which was not previously discovered as a target in EoE or any other allergic disease.

The role of clinical response to treatment in determining pathogenicity of genomic variants

2020 ◽  
Author(s):  
Joseph J. Shen ◽  
Saskia B. Wortmann ◽  
Lonneke de Boer ◽  
Leo A. J. Kluijtmans ◽  
Marleen C. D. G. Huigen ◽  
...  
Keyword(s):  
Clinical Response ◽  
Response To Treatment ◽  
Genomic Variants

scholarly journals Rare cytogenetic abnormalities and alteration of microRNAs in acute myeloid leukemia and response to therapy

2015 ◽  
Author(s):  
Mohammad Shahjahani ◽  
Elham Khodadi ◽  
Mohammad Seghatoleslami ◽  
Javad Mohammadi Asl ◽  
Neda Golchin ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Who Classification ◽  
Genetic Alterations ◽  
Response To Therapy ◽  
Response To Treatment ◽  
Cytogenetic Abnormalities ◽  
Myeloid Leukemias ◽  
Acute Myeloid

Acute myeloid leukemia (AML) is the most common acute leukemia in adults, which is heterogeneous in terms of morphological, cytogenetic and clinical features. Cytogenetic abnormalities, including karyotype aberrations, gene mutations and gene expression abnormalities are the most important diagnostic tools in diagnosis, classification and prognosis in acute myeloid leukemias. Based on World Health Organization (WHO) classification, acute myeloid leukemias can be divided to four groups. Due to the heterogeneous nature of AML and since most therapeutic protocols in AML are based on genetic alterations, gathering further information in the field of rare disorders as well as common cytogenetic abnormalities would be helpful in determining the prognosis and treatment in this group of diseases. Recently, the role of microRNAs (miRNAs) in both normal hematopoiesis and myeloid leukemic cell differentiation in myeloid lineage has been specified. miRNAs can be used instead of genes for AML diagnosis and classification in the future, and can also play a decisive role in the evaluation of relapse as well as response to treatment in the patients. Therefore, their use in clinical trials can affect treatment protocols and play a role in therapeutic strategies for these patients. In this review, we have examined rare cytogenetic abnormalities in different groups of acute myeloid leukemias according to WHO classification, and the role of miRNA expression in classification, diagnosis and response to treatment of these disorders has also been dealt with.

Concentrations of doxycycline and penicillin G in sera and cerebrospinal fluid of patients treated for neuroborreliosis.

1996 ◽  
Vol 40 (5) ◽  
pp. 1104-1107 ◽  
Author(s):  
M Karlsson ◽  
S Hammers ◽  
I Nilsson-Ehle ◽  
A S Malmborg ◽  
B Wretlind
Keyword(s):  
Cerebrospinal Fluid ◽  
Borrelia Burgdorferi ◽  
Treatment Failure ◽  
Clinical Response ◽  
Drug Administration ◽  
Drug Concentration ◽  
Response To Treatment ◽  
Penicillin G ◽  
Good Clinical Response

Concentrations of doxycycline and penicillin G in serum and cerebrospinal fluid (CSF) were analyzed in 46 patients during treatment for neuroborreliosis. Twenty patients were treated intravenously with penicillin G at 3 g every 6 h (q6h), and 26 patients were treated orally with doxycycline at 200 mg q24h. All samples were collected on day 13 of treatment. The median concentrations of penicillin G in serum were 0.5, 37, and 5.6 micrograms/ml before and 1 and 3 h after drug administration, and that in CSF was 0.5 (range, 0.3 to 1.6) microgram/ml after 2 to 3 h. The median concentrations of doxycycline in serum were 2.1, 6.1, and 4.7 micrograms/ml before and 2 and 6 h after drug administration, and that in CSF was 0.6 (range, 0.4 to 2.5) microgram/ml after 4 h. All patients had concentrations of penicillin G or doxycycline in CSF above the lowest reported MICs of penicillin G (0.003 microgram/ml) and doxycycline (0.12 microgram/ml) for Borrelia burgdorferi. However, no patients had a drug concentration in CSF above the highest reported MIC of penicillin G (8 micrograms/ml), and only one had a drug concentration in CSF above the highest reported MIC of doxycycline (2 micrograms/ml), despite good clinical response to treatment. No treatment failure or relapse was observed during a 1-year follow-up, although one patient treated with penicillin G and one treated with doxycycline were retreated because of residual pain. The chosen dosages of penicillin G and doxycycline seem to give sufficient concentrations in serum and CSF for the treatment of neuroborreliosis.

scholarly journals The Potential Role of Genomic Medicine in the Therapeutic Management of Rheumatoid Arthritis

2019 ◽  
Vol 8 (6) ◽  
pp. 826 ◽  
Author(s):  
Marialbert Acosta-Herrera ◽  
David González-Serna ◽  
Javier Martín
Keyword(s):  
Rheumatoid Arthritis ◽  
Large Scale ◽  
Rare Variants ◽  
Drug Repositioning ◽  
Genomic Medicine ◽  
Response To Therapy ◽  
Response To Treatment ◽  
Genomic Studies ◽  
The Right

During the last decade, important advances have occurred regarding understanding of the pathogenesis and treatment of rheumatoid arthritis (RA). Nevertheless, response to treatment is not universal, and choosing among different therapies is currently based on a trial and error approach. The specific patient’s genetic background influences the response to therapy for many drugs: In this sense, genomic studies on RA have produced promising insights that could help us find an effective therapy for each patient. On the other hand, despite the great knowledge generated regarding the genetics of RA, most of the investigations performed to date have focused on identifying common variants associated with RA, which cannot explain the complete heritability of the disease. In this regard, rare variants could also contribute to this missing heritability as well as act as biomarkers that help in choosing the right therapy. In the present article, different aspects of genetics in the pathogenesis and treatment of RA are reviewed, from large-scale genomic studies to specific rare variant analyses. We also discuss the shared genetic architecture existing among autoimmune diseases and its implications for RA therapy, such as drug repositioning.

Sign in / Sign up

Export Citation Format

Share Document